Art. -Nr.: HY-101488

CC-885

20 Cited Publications

Kundenbewertung

Based on 20 publication(s) in Google Scholar

CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.26%
CAS. Nr.: 1010100-07-8
Formel: C₂₂H₂₁ClN₄O₄
Molecular Weight:440.88

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

CC-885 Chemical Structure

CAS. Nr.: 1010100-07-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (20)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.

IC₅₀ & Target

Cereblon

Alle Ligands for E3 Ligase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BE(2)-C	EC₅₀	<5 nM Compound: CC-885	Antiproliferative activity against wild type human BE2C cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay Antiproliferative activity against wild type human BE2C cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay	[PMID: 38608634]
HK-2	IC₅₀	0.002 μM Compound: 154; CC-885	Downregulation of BNIP3 expression in human HK-2 cells incubated for 6 hrs by Western blot analysis Downregulation of BNIP3 expression in human HK-2 cells incubated for 6 hrs by Western blot analysis	[PMID: 38295689]
HL-60	IC₅₀	0.003 μM Compound: 3; CC-885	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
JeKo-1	IC₅₀	1.2 nM Compound: CC-885	Antiproliferative activity against human JeKo1 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human JeKo1 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
Kasumi 1	IC₅₀	0.01 μM Compound: 3; CC-885	Antiproliferative activity against human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human Kasumi 1 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
Kasumi 1	IC₅₀	0.8 nM Compound: CC-885	Antiproliferative activity against human Kasumi-1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Kasumi-1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
KG-1	IC₅₀	0.007 μM Compound: 3; CC-885	Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
KG-1a	IC₅₀	0.008 μM Compound: 3; CC-885	Antiproliferative activity against human KG-1a cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human KG-1a cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
MCF-10A	IC₅₀	0.005 μM Compound: CC-885	Cytotoxicity against human MCF10A cells after 72 hrs by MTS assay Cytotoxicity against human MCF10A cells after 72 hrs by MTS assay	[PMID: 29795767]
MM1.S	IC₅₀	0.3 nM Compound: CC-885	Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MM1S cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MOLM-13	IC₅₀	0.008 μM Compound: 3; CC-885	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
MOLT-4	EC₅₀	<1 nM Compound: CC-885	Antiproliferative activity against wild type human MOLT-4 cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay Antiproliferative activity against wild type human MOLT-4 cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay	[PMID: 38608634]
MV4-11	EC₅₀	<1 nM Compound: CC-885	Antiproliferative activity against wild type human MV4-11 cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay Antiproliferative activity against wild type human MV4-11 cells assessed as reduction in cell viability measured after 3 days by ATP-dependent luminescence assay	[PMID: 38608634]
MV4-11	IC₅₀	0.005 μM Compound: 3; CC-885	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
MV4-11	IC₅₀	0.2 nM Compound: CC-885	Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human MV411 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
MV4-11	IC₅₀	0.3 nM Compound: CC-885	Antiproliferative activity against human MV411 cells after 72 hrs by MTS assay Antiproliferative activity against human MV411 cells after 72 hrs by MTS assay	[PMID: 29795767]
NB-4	IC₅₀	0.002 μM Compound: 3; CC-885	Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
OCI-AML2	IC₅₀	0.021 μM Compound: 3; CC-885	Antiproliferative activity against human OCI-AML2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human OCI-AML2 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
OCI-AML-3	IC₅₀	0.073 μM Compound: 3; CC-885	Antiproliferative activity against human OCI-AML3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human OCI-AML3 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
PBMC	IC₅₀	>5 μM Compound: 3; CC-885	Cytotoxicity against PBMC (unknown origin) Cytotoxicity against PBMC (unknown origin)	[PMID: 32130004]
PBMC	IC₅₀	0.3 nM Compound: CC-885	Cytotoxicity against human PBMC cells by CellTiter96 Aqueous non-radioactive cell proliferation assay Cytotoxicity against human PBMC cells by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
Raji	IC₅₀	20.4 nM Compound: CC-885	Antiproliferative activity against human Raji cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Raji cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
RPMI-8226	IC₅₀	5.5 nM Compound: CC-885	Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
SNU-C4	CC₅₀	440 nM Compound: CC-885	Cytotoxicity against PXR knock in human SNU-C4 cells measured after 72 hrs by celltiter-glo assay Cytotoxicity against PXR knock in human SNU-C4 cells measured after 72 hrs by celltiter-glo assay	[PMID: 35978691]
THLE-2	IC₅₀	0.011 μM Compound: 3; CC-885	Cytotoxicity against human THLE-2 cells assessed as cell viability incubated for 72 hrs by cell titer glo assay Cytotoxicity against human THLE-2 cells assessed as cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
THP-1	IC₅₀	1.5 nM Compound: CC-885	Antiproliferative activity against human THP1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human THP1 cells measured after 168 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
U-266	IC₅₀	2 nM Compound: CC-885	Antiproliferative activity against human U266 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human U266 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]
U-937	IC₅₀	0.011 μM Compound: 3; CC-885	Antiproliferative activity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer glo assay	[PMID: 33591756]
WI-38	IC₅₀	>20 μM Compound: CC-885	Cytotoxicity against human WI38 cells after 72 hrs by MTS assay Cytotoxicity against human WI38 cells after 72 hrs by MTS assay	[PMID: 29795767]
Z-138	IC₅₀	0.4 nM Compound: CC-885	Antiproliferative activity against human Z138 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Antiproliferative activity against human Z138 cells measured after 72 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 31125896]

In Vitro

Acute myeloblatlic leukemia (AML) cell lines, human liver epithelial cell line (THLE-2) and human peripheral blood mononuclear cells (PBMC) are treated with varying concentrations of CC-885, with IC₅₀s of 10×^-6-1 μM. The effect of CC-885 on cell proliferation in AML cell lines, THLE-2 and human PBMC is more powerful than Lenalidomide and Pomalidomide with IC₅₀s>10 μM. To address whether the cereblon-dependent degradation of GSPT1 is responsible for the cytotoxic effects of CC-885, a GSPT1 mutant that retains its normal function, but loses CC-885-dependent cereblon binding, is used to distinguish the role of GSPT1 from that of other substrates. CC-885 is tested in 293T HEK cells stably expressing the CC-885-sensitive or -resistant GSPT1 variants. Overexpression of a resistant variant GSPT1Δ(1–138)/(G575N) completely abrogate the CC-885-induced anti-proliferation, whereas overexpression of a CC-885-sensitive variant GSPT1Δ(1-138) only confer partial protection. Similar results are obtained in AML cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1010100-07-8
Appearance Solid
Molecular Weight 440.88
Formel C₂₂H₂₁ClN₄O₄
Color White to off-white
SMILES

O=C(NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1)NC4=CC=C(C)C(Cl)=C4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (20)

All WBCell Proliferation/Viability AssayRT-PCR

Sort by:

Journal Impact Factor

Cell

Mechanisms of readthrough mitigation reveal principles of GCN1-mediated translational quality control. [Abstract]

2023 Jul 20;186(15):3227-3244.e20. PMID: 37339632

CC-885 purchased from MedChemExpress. Usage Cited in: Cell. 2023 Jul 20;186(15):3227-3244.e20. [Abstract]

Immunoblot analysis of eRF3 upon treatment of HEK293T cells with CC-885 (10 nM) and G418 (20 μg/mL) for 4 h to induce readthrough (n = 3).
Cancer Discov

TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers. [Abstract]

2026 Apr 19. PMID: 42001523
Nat Commun

A degron-mimicking molecular glue drives CRBN homo-dimerization and degradation. [Abstract]

2025 Nov 19;16(1):10157. PMID: 41258141
Nat Commun

Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery. [Abstract]

2023 Dec 19;14(1):8437. PMID: 38114468

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Dec 19;14(1):8437. [Abstract]

Degradation of neo-substrates by CC-885 (0.00001-10000 nM) in MM.1 S cells after 16 h treatment. Graph bars represent mean values ± SD. n = 3 independent biological replicates. Immunoblot experiment was performed to check protein level. Quantitative protein analysis was performed by software Image J. Source data are provided as a Source Data file.

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Dec 19;14(1):8437. [Abstract]

Western blot using lysates from Ba/F3 cells overexpressing Crbn constructs with combinations of humanization mutations E152D, V380E, and I391V as indicated. Protein lysates were harvested following 6 hours of treatment with 1 μM CC-885.
Nat Commun

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. [Abstract]

2022 Sep 10;13(1):5324. PMID: 36088459

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]

RT-qPCR data showing expression of COL1A1 and COL3A1 upon treatment of LX2 cells (left panel) or EMS404 cells (right panel) with increasing concentrations of CC-885 (0.001-1 μM) or vehicle for 24h (n=3 biologically independent experiments). Log2 FC between drug and vehicle-treated cells are shown. The bar graph shows means ±SD.
Mol Cell

Mechanism of RACK1-dependent ZAKα activation at stalled and collided ribosomes. [Abstract]

2026 Jun 18;86(12):2341-2357.e10. PMID: 42214329
Nat Chem Biol

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates. [Abstract]

2024 Sep;20(9):1227-1236. PMID: 38514884

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2024 Sep;20(9):1227-1236. [Abstract]

GSPT1, VCL and ETF1 proteins in 293T cells treated with CC-885 (1 μM; 0.5-24 h) over the indicated time course were analyzed by immunoblotting.
J Clin Invest

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. [Abstract]

2022 Aug 15;132(16):e153514. PMID: 35763353

CC-885 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2022 Aug 15;132(16):e153514. [Abstract]

Cell viability in MOLM13 cells expressing GSPT1-ETF1Δ (drug sensitive and drug resistant; G575N). For all CellTiter-Glo luminescent assays, cell viability was assessed 72 hours after treatment with CC-885 (0.001-1 μM, graphs represent combined data from 3 biological replicates performed in technical triplicate; symbols represent mean ± SEM).
Acta Pharmacol Sin

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. [Abstract]

2020 Sep;41(9):1246-1254. PMID: 32210356
Cell Chem Biol

A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. [Abstract]

2020 Jul 16;27(7):866-876.e8. PMID: 32413286
Leukemia

Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. [Abstract]

2025 Sep;39(9):2163-2173. PMID: 40670672
Mol Ther Oncolytics

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. [Abstract]

2020 Jun 23;18:215-225. PMID: 32728610
Bioorg Chem

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. [Abstract]

2022 Feb:119:105505. PMID: 34838332
Cell Signal

Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression. [Abstract]

2025 Jun:130:111665. PMID: 39986359
J Proteome Res

SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics. [Abstract]

2022 Aug 5;21(8):1842-1856. PMID: 35848491
Dis Model Mech

Recovery of α-L-Fucosidase in Fucosidosis nonsense variants by readthrough stimulation and release factor degradation. [Abstract]

2025 Nov 7:dmm.052495. PMID: 41200823
Biochem Biophys Res Commun

Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. [Abstract]

2021 Apr 16:549:150-156. PMID: 33676183
bioRxiv

2026 Feb 16.
bioRxiv

Slice-PASEF: Maximising Ion Utilisation in LC-MS Proteomics. [Abstract]

2025 Sep 2:2022.10.31.514544. PMID: 40950106
bioRxiv

2024 Jan 28.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (151.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2682 mL

11.3410 mL

22.6819 mL

5 mM

0.4536 mL

2.2682 mL

4.5364 mL

10 mM

0.2268 mL

1.1341 mL

2.2682 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.25 mg/mL (5.10 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.25 mg/mL (5.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Human cancer cell lines cultured in the growth medium are seeded into black 384-well plates containing DMSO or test compounds such as CC-885 (10×^-6-1 μM). The seeding density for each cell line is optimized to allow the cell growth in the linear range during a 3-day culture period. To test the compound effect on cell proliferation in acute myeloid leukaemia (AML) cell lines, 5,000 to 10,000 cells per well in 200 μl complete culture media are seeded into black 96-well plates containing DMSO or test compounds such as CC-885. After 48 or 72 h, cell proliferation is assessed using the CellTiter-Glo (CTG) Luminescent Cell Viability Assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mary E. Matyskiela, et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature. 2016 Jul 14;535(7611):252-7. [Content Brief]

[2]. Jochem M, et al. Degradome analysis to identify direct protein substrates of small-molecule degraders[J]. bioRxiv, 2024: 2024.01. 28.577572.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2682 mL	11.3410 mL	22.6819 mL	56.7048 mL
	5 mM	0.4536 mL	2.2682 mL	4.5364 mL	11.3410 mL
	10 mM	0.2268 mL	1.1341 mL	2.2682 mL	5.6705 mL
	15 mM	0.1512 mL	0.7561 mL	1.5121 mL	3.7803 mL
	20 mM	0.1134 mL	0.5670 mL	1.1341 mL	2.8352 mL
	25 mM	0.0907 mL	0.4536 mL	0.9073 mL	2.2682 mL
	30 mM	0.0756 mL	0.3780 mL	0.7561 mL	1.8902 mL
	40 mM	0.0567 mL	0.2835 mL	0.5670 mL	1.4176 mL
	50 mM	0.0454 mL	0.2268 mL	0.4536 mL	1.1341 mL
	60 mM	0.0378 mL	0.1890 mL	0.3780 mL	0.9451 mL
	80 mM	0.0284 mL	0.1418 mL	0.2835 mL	0.7088 mL
	100 mM	0.0227 mL	0.1134 mL	0.2268 mL	0.5670 mL

Keywords

CC-885

20 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CC-885

MCE Bioactive Compound Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) CC-885

Alle Ligands for E3 Ligase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (20)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CC-885

MCE Bioactive Compound Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) CC-885

Alle Ligands for E3 Ligase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (20)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CC-885 Related Classifications

HY-101488 Related Classifications